PerkinElmer to Acquire BioLegend for $5.25B

 PerkinElmer to Acquire BioLegend for $5.25B


  • PerkinElmer to acquire BioLegend for ~$5.25B in cash and stock transaction. The acquisition is expected to close by the end of 2021
  • The acquisition will allow PerkinElmer to build its growth in areas such as clinical diagnostics and food safety testing
  • With the acquisition, BioLegend’s San Diego, California-based campus will become the global center for the development of chemical reagents used in medical research for the combined company

Click here ­to­ read the full press release/ article | Ref: PRNewswire | Image: BioLegend

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post